SCHEMBL165748

SCHEMBL165748

CCNC(=O)c1ccnnc1[O]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.41
KMT2A Q03164 1/20 0.41
CHIA Q9BZP6 1/20 0.40
LMNA P02545 1/20 0.39
ADRA1D P25100 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
BRD4 O60885 2/20 0.38
CA1 P00915 1/20 0.36
GAA P10253 1/20 0.36
CA9 Q16790 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
P2RX7 Q99572 1/20 0.35
HPGD P15428 1/20 0.35
POLB P06746 1/20 0.34
THRB P10828 1/20 0.34
RECQL P46063 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163082 0.87 POLB (0.49) L3MBTL1KMT2AADRA1DADRA1AADRA1B
SCHEMBL163036 0.84 TSHR (0.57) L3MBTL1LMNAADRA1DADRA1AADRA1B
SCHEMBL162468 0.82 KMT2A (0.45) KMT2ALMNAADRA1DADRA1AADRA1B
SCHEMBL161696 0.80 GAA (0.40) ADRA1DADRA1AADRA1BBRD4GAA
SCHEMBL161246 0.78 MEN1 (0.53) L3MBTL1KMT2ALMNAADRA1ATSHR
SCHEMBL164540 0.76 CHIA (0.56) L3MBTL1KMT2ACHIALMNAADRA1D
SCHEMBL163192 0.76 POLB (0.42) L3MBTL1KMT2ALMNAGAATSHR
SCHEMBL161919 0.76 ALOX5 (0.41) LMNAADRA1DADRA1AADRA1BGAA
SCHEMBL162113 0.73 KDM4E (0.47) L3MBTL1LMNACA1GAACA9
SCHEMBL160323 0.72 TSHR (0.52) KMT2ACA1CA9TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS SMN1; SMN2, SOD1, SOD3 L3MBTL1 1654/4885KMT2A 2544/4885CHIA 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.